ABCL AbCellera Bio: Forward P/S Multiple
AbCellera Biologics (ABCL) generates revenue through payments and royalties for access to its AI-driven antibody discovery system. Business development relies on licensing agreements with big pharma behemoths and government subsidies. Growth prospects are driven by the acceleration of drug discovery via neural networks. P/S expectations for the company reflect volatile market sentiment, with the 55.30 mark serving as a key metric for the real-time valuation of the asset.
ABCL (AbCellera Bio): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- financial results and valuation multiples details:
ABCL - Final Profit|Projected Future Earnings AbCellera Biologics|ABCL - P/E Multiple|Projected Price to Earnings AbCellera Biologics Inc.|ABCL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple AbCellera Bio|ABCL - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) AbCellera|ABCL - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months abcellera.com|ABCL - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year AbCellera Biologics
- sales revenue and business income indicators:
Summary company analytics:ABCL (AbCellera)
The fundamental assessment of business quality is based on the ratio of an asset's current value to its future cash flows. The forward P/S measures market capitalization relative to projected annual revenue, allowing for an evaluation of the extent of market expectations already priced in. For AbCellera Biologics (ABCL), this ratio reflects the value of rights to future royalties from its AI antibody discovery platform. By analyzing the dynamics of the forward P/S, an investor can promptly track the flow of liquidity between assets.
Who AbCellera Biologics competes with
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA - Forward P/S Multiple|PTGX: Forward P/S Multiple|IMVT (immunovant.com) - Price-to-Projected Revenue Ratio|KNSA (Kiniksa) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Grifols SA (GRFS)|Forward P/S Multiple ADPT|CLDX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|biocryst.com - Price-to-Projected Revenue Ratio|VERA - Price-to-Projected Revenue Ratio|DNTH: Price-to-Projected Revenue Ratio|PHVS: Forward P/S Multiple|Market Cap to Future Revenue Ratio Tourmaline (TRML)|Price-to-Projected Revenue Ratio Precigen, Inc.|PHAR: Forward Price to Sales|Forward P/S Multiple NKTR|Forward P/S Multiple Upstream Bio, Inc. (UPB)|Zenas Biopharma, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales IMNM|Gossamer Bio, Inc. - Forward P/S Multiple|KALV: Price-to-Projected Revenue Ratio|SEPN: Forward P/S Multiple|PVLA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Savara Corp|Market Cap to Future Revenue Ratio Rigel Corp RIGL|Price-to-Projected Revenue Ratio AnaptysBio, Inc. (ANAB)|Price-to-Projected Revenue Ratio ATXS (astriatx.com)|Price-to-Projected Revenue Ratio enGene ENGN|RAPT Therapeutics Inc. (RAPT) - Market Cap to Future Revenue Ratio|Aerovate - Forward P/S Multiple|Projected Price to Revenue Aclaris Therapeutics, Inc (ACRS)|KYTX: Forward P/S Multiple|TLSA - Market Cap to Expected Sales Ratio|CABA (Cabaletta Bio) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Ventyx Biosciences Inc. (VTYX)|Price-to-Projected Revenue Ratio Theratechnologies Inc (THTX)|Market Cap to Expected Sales Ratio Avalo Therapeutics Inc|Forward P/S Multiple ELDN (Eledon Pharmaceuticals)|Forward P/S Multiple agenusbio.com AGEN|Climb Bio - Forward P/S Multiple|ZURA: Price-to-Projected Revenue Ratio|ATYR: Forward P/S Multiple|Forward Price-to-Revenue Multiple Adagene Inc.|Price-to-Projected Revenue Ratio ImageneBio|Price-to-Projected Revenue Ratio STTK|Price-to-Projected Revenue Ratio Equillium, Inc. (EQ)|CNTB: Future Price to Revenue|Forward P/S Multiple IMUX (Immunic)|Forward Price to Sales ATRA|InflaRx GmbH - Forward P/S Multiple|XFOR - Forward P/S Multiple|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Celularity - Forward Price to Sales|Price-to-Projected Revenue Ratio INmune Bio Corp|Forward Price-to-Revenue Multiple Barinthus Biotherapeutics Corp (BRNS)|Forward P/S Multiple KZR|Forward P/S Multiple sabbiotherapeutics.com (SABS)|Akari Therapeutics Plc - Forward Price-to-Revenue Multiple|Forward Price to Sales ENLV|Q32 Bio Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio GeoVax Corp GOVX|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ibioinc.com|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Forward Price-to-Revenue Multiple XTL Biopharmaceuticals Ltd (XTLB)|Forward Price-to-Revenue Multiple BOLT (Bolt Biotherapeutics)|Forward P/S Multiple hcwbiologics.com (HCWB)|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM: Market Cap to Projected Revenue|Aditxt Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio GRI Bio Inc|XRTX: Forward P/S Multiple|Vyome Therapeutics (HIND) - Forward P/S Multiple|REVB (Revelation Biosciences) - Forward P/S Multiple|Price-to-Projected Revenue Ratio INDP|Forward P/S Multiple SCNI|Forward Price-to-Revenue Multiple calcimedica.com CALI|Forward P/S Multiple AFMD (Affimed N.V.)|Allakos Inc (ALLK) - Market Cap to Future Revenue Ratio|HOOK - Price-to-Projected Revenue Ratio|IGMS: Price-to-Projected Revenue Ratio|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|OCEA (Ocean Biomedical Inc) - Price-to-Projected Revenue Ratio|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Third Harmonic Bio Inc THRD
